Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 500087 | NSE: CIPLA

NSE BSE
1509.90
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1487.00
  •  1516.00
  •  1486.00
  •  1480.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2188675
  •  32977.29
  •  1600.00
  •  1108.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 127,452.07
  • 29.62
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 126,824.12
  • 0.82%
  • 4.77

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.91%
  • 0.50%
  • 14.24%
  • FII
  • DII
  • Others
  • 27.82%
  • 23.01%
  • 3.52%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.38
  • 6.82
  • 5.90

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.87
  • 11.71
  • 3.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.19
  • 12.67
  • 5.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.02
  • 30.28
  • 30.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.58
  • 3.66
  • 3.94

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.30
  • 15.52
  • 16.26

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Net Sales
6,693.94
6,328.89
5.77%
6,163.24
5,739.30
7.39%
6,603.81
5,810.09
13.66%
6,678.15
5,828.54
14.58%
Expenses
4,978.14
4,834.98
2.96%
4,847.38
4,565.56
6.17%
4,856.28
4,402.54
10.31%
4,944.40
4,526.21
9.24%
EBITDA
1,715.80
1,493.91
14.85%
1,315.86
1,173.74
12.11%
1,747.53
1,407.55
24.15%
1,733.75
1,302.33
33.13%
EBIDTM
25.63%
23.60%
21.35%
20.45%
26.46%
24.23%
25.96%
22.34%
Other Income
160.19
136.29
17.54%
249.33
134.63
85.20%
184.63
114.44
61.33%
176.32
122.95
43.41%
Interest
17.95
16.39
9.52%
17.59
34.36
-48.81%
30.10
31.82
-5.41%
25.80
25.55
0.98%
Depreciation
246.68
239.21
3.12%
288.34
346.22
-16.72%
233.43
272.11
-14.21%
290.04
299.37
-3.12%
PBT
1,611.36
1,374.60
17.22%
1,259.26
745.37
68.94%
1,473.81
1,218.06
21.00%
1,594.23
1,100.36
44.88%
Tax
435.07
378.02
15.09%
324.86
222.25
46.17%
405.30
410.01
-1.15%
438.41
302.60
44.88%
PAT
1,176.29
996.58
18.03%
934.40
523.12
78.62%
1,068.51
808.05
32.23%
1,155.82
797.76
44.88%
PATM
17.57%
15.75%
15.16%
9.11%
16.18%
13.91%
17.31%
13.69%
EPS
14.58
12.33
18.25%
11.63
6.51
78.65%
13.08
9.92
31.85%
14.01
9.78
43.25%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
26,139.14
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
Net Sales Growth
10.26%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
 
Cost Of Goods Sold
8,775.62
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
Gross Profit
17,363.52
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
GP Margin
66.43%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
Total Expenditure
19,626.20
17,762.83
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
Power & Fuel Cost
-
353.61
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
% Of Sales
-
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
Employee Cost
-
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
% Of Sales
-
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
Manufacturing Exp.
-
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
% Of Sales
-
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
General & Admin Exp.
-
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
% Of Sales
-
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
Selling & Distn. Exp.
-
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
% Of Sales
-
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
Miscellaneous Exp.
-
619.43
565.55
508.00
692.12
855.40
968.98
645.54
657.29
497.67
680.32
% Of Sales
-
2.72%
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
EBITDA
6,512.94
4,990.29
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
EBITDA Margin
24.92%
21.93%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
Other Income
770.47
512.13
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
Interest
91.44
109.54
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
Depreciation
1,058.49
1,172.11
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
372.64
PBT
5,938.66
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
Tax
1,603.64
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
Tax Rate
27.00%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
PAT
4,335.02
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
PAT before Minority Interest
4,307.40
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
Minority Interest
-27.62
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
PAT Margin
16.58%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
PAT Growth
38.70%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
 
EPS
53.77
34.79
31.38
29.99
19.77
19.16
17.53
12.57
17.02
14.96
17.37

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
Share Capital
161.43
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
Total Reserves
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
Non-Current Liabilities
183.53
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
Secured Loans
332.46
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
Unsecured Loans
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
Long Term Provisions
102.16
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
Current Liabilities
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
Trade Payables
2,457.05
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
Other Current Liabilities
1,085.07
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
Short Term Borrowings
187.90
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
Short Term Provisions
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
Total Liabilities
28,930.34
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
Net Block
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
Gross Block
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
Accumulated Depreciation
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
Non Current Assets
11,731.79
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
Capital Work in Progress
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
Non Current Investment
572.52
355.63
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
Long Term Loans & Adv.
845.11
736.39
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
Other Non Current Assets
60.38
383.22
102.51
77.61
166.82
255.71
210.06
176.54
168.88
158.89
Current Assets
16,805.06
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
Current Investments
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
Inventories
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
Sundry Debtors
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
Cash & Bank
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
Other Current Assets
2,937.15
305.56
347.54
442.02
1,566.48
1,599.13
1,226.01
1,223.17
858.67
630.63
Short Term Loans & Adv.
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
Net Current Assets
11,771.79
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
Total Assets
28,536.85
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
PBT
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
Adjustment
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
Changes in Working Capital
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
Cash after chg. in Working capital
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
Net Fixed Assets
-637.57
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
Net Investments
-935.67
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
Others
-815.27
-425.89
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
Cash from Financing Activity
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
Net Cash Inflow / Outflow
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
Opening Cash & Equivalents
658.11
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
143.01
Closing Cash & Equivalent
561.33
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26
175.76

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
289.24
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
ROA
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
ROE
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
ROCE
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
Fixed Asset Turnover
1.81
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
1.47
Receivable days
44.13
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
Inventory Days
61.98
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
Payable days
109.80
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
44.93
Cash Conversion Cycle
-3.69
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
107.41
Total Debt/Equity
0.02
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
Interest Cover
37.87
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • USFDA classifies Cipla’s Patalganga manufacturing facility as Voluntary Action Indicated
    25th Jun 2024, 18:21 PM

    USFDA had concluded routine current Good Manufacturing Practices (cGMP) inspection at Cipla’s said facility from March 28, 2024 to April 4, 2024

    Read More
  • USFDA conducts inspection at Cipla’s manufacturing facility in Goa
    22nd Jun 2024, 12:22 PM

    On conclusion of the inspection, the company received 6 inspectional observations in Form 483

    Read More
  • Cipla’s arm to invest additional EUR 3 million in Ethris GmbH
    18th Jun 2024, 15:42 PM

    This additional investment through a convertible loan will accelerate Cipla’s participation in the mRNA space

    Read More
  • Cipla gets USFDA’s final nod for Lanreotide injection
    22nd May 2024, 11:42 AM

    Cipla’s Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (lanreotide) Injection

    Read More
  • Cipla inks pact to make additional investment in Achira Labs
    16th May 2024, 10:58 AM

    This expanded investment will enhance its collective abilities to ensure access to point of care test solutions

    Read More
  • Cipla’s promoters sell 2.53% stake in company
    15th May 2024, 16:59 PM

    Post transaction, the entire promoter group continues to hold 31.67 per cent in the company

    Read More
  • Cipla reports 79% rise in Q4 consolidated net profit
    10th May 2024, 15:26 PM

    Total consolidated income of the company increased by 9.17% at Rs 6,412.57 crore for Q4FY24

    Read More
  • Cipla - Quarterly Results
    10th May 2024, 14:30 PM

    Read More
  • Cipla's arm acquires business undertaking from Ivia Beaute
    29th Apr 2024, 10:30 AM

    This strategic move is aligned with Cipla’s focus on enhancing its consumer healthcare and wellness portfolio

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.